Continuous Local Anesthetic Infusion Following Hernia Repair

NCT ID: NCT01804114

Last Updated: 2021-01-29

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

31 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-03-31

Study Completion Date

2015-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary endpoint of this study will determine if subjects receiving a continuous infusion of local anesthetic following laparoscopic ventral hernia repair, with the pain pump installed as described to treat post surgical pain will have a lower incidence of pain than those patients treated with a placebo, saline-filled pain pump.The secondary endpoint of this study will determine if subjects receiving a continuous infusion of local anesthetic following laparoscopic ventral hernia repair, with the pain pump installed as described to treat post surgical pain will have a lower utilization of narcotic analgesic medication than those patients treated with the placebo, saline-filled pain pump.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients will be screened to determine study eligibility using inclusion/exclusion criteria. Following the consent process, subjects will be randomly assigned to a treatment arm (anesthetic or placebo group). Baseline data will be collected prior surgical implantation of the pain pump delivery system. Both study and control groups will be able to receive supplemental medication for breakthrough pain as determined by the surgeon. Post-operative data will be collected up to three weeks following surgery.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ventral Hernia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Local anesthetic continuous infusion

Pain management following hernia repair

Group Type ACTIVE_COMPARATOR

Pain management following hernia repair

Intervention Type PROCEDURE

Continuous infusion of local anesthetic via pain pump following hernia repair

Placebo continuous infusion

Placebo pain management following hernia repair

Group Type PLACEBO_COMPARATOR

Placebo for pain management following hernia repair

Intervention Type PROCEDURE

Continuous infusion of placebo via pain pump following hernia repair

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pain management following hernia repair

Continuous infusion of local anesthetic via pain pump following hernia repair

Intervention Type PROCEDURE

Placebo for pain management following hernia repair

Continuous infusion of placebo via pain pump following hernia repair

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Placement of pain pump to manage post-operative hernia pain Placement of placebo pain pump

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\>18 years

* ASA I,II,III
* Scheduled for Laparoscopic Ventral Hernia Repair

Exclusion Criteria

* ASA IV or greater
* Needing emergency surgery
* Known history of drug abuse
* GI, liver, kidney or other condition which, per the surgeon's opinion, could interfere with the absorption, distribution, metabolism or excretion of any drug used during the duration of the study
* Patients with a prior allergic reaction or dependency to morphine, demerol, dilaudid, fentanyl, marcaine(bupivicaine), lidocaine, or ropivicaine.
Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Kimberly-Clark Corporation

INDUSTRY

Sponsor Role collaborator

Endeavor Health

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Michael Ujiki MD

Director of Minimally Invasive Surgery

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Michael Ujiki, MD

Role: PRINCIPAL_INVESTIGATOR

Endeavor Health

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

NorthShore University HealthSystem

Evanston, Illinois, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EH11-297

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.